

Your reference
Our reference
Date

July 31, 2025

Changes to BNP Paribas Funds (“BNP”) and the Underlying Fund (as defined below)

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.

**Zurich International Life
Limited**

(a company incorporated in
the Isle of Man with limited liability)

25-26/F, One Island East
18 Westlands Road
Island East, Hong Kong

Website: www.zurich.com.hk

Zurich International Life Limited
provides life assurance, investment
and protection products and is
authorized by the Isle of Man
Financial Services Authority.

Registered in the Isle of Man
number 20126C.

Registered office: Zurich House,
Isle of Man Business Park,
Douglas, Isle of Man, IM2 2QZ,
British Isles

We accept full responsibility for the accuracy of the content of this document.

Dear valued customer,

We are writing to let you know about the changes to BNP and the Underlying Fund. You have invested in the investment choice corresponding to the Underlying Fund, which is listed in the “Which investment choice is affected?” table below under the column “Name and code of the investment choice”.

Which investment choice is affected?

Name and code of the investment choice (the “Investment Choice”)	Name of the corresponding underlying fund (the “Underlying Fund”)	Applicable scheme (Collectively, the “Schemes”)
ZI BNP Paribas Funds Emerging Bond Opportunities (Code: KAUSD)	BNP Paribas Funds Emerging Bond Opportunities	<ul style="list-style-type: none"> Elite International Bond Futura II Futura III SUPRA Savings and Investment Plan Vista Vista Retirement Scheme

What is happening?

We have been notified by the board of directors of BNP (the “**Board**”) of the following changes to the Underlying Fund that will be incorporated in the next version of the Hong Kong offering document of BNP (the “**Offering Document**”) and will be effective on August 12, 2025, unless other indicated below.

Changes to Book I of the Prospectus of BNP (the “Prospectus”)

A risk factor relating to capital gain tax will be inserted in “Appendix 3 – Investment Risks” of Book I of the Prospectus and will read as follows:

“Investors’ attention is drawn to the fact that selling operations of securities by the sub-funds may be subject to short and long-terms taxes on capital gains. Investors subscribing in shares of the sub-funds should know that the net asset value per share of these sub-funds may therefore be impacted by these taxes. This applies particularly but not only to Indian tax (see Book II).”

A cross-reference to this risk factor will, in particular, be inserted in the risk profile of the Underlying Fund

As confirmed by the Board, the changes above will not result in any increment in fees level or costs in managing the Underlying Fund. In addition, no costs or expenses will be incurred in connection with the changes. The changes would not materially change the features and overall risk profile of the Underlying Fund. There would be no change in the operations or the manner in which the Underlying Fund is being managed. Further, the changes would not materially prejudice the existing investors’ rights of interest.

The Hong Kong Offering Document will be updated to reflect the change above. The current Hong Kong Offering Document is available on the website at <https://www.bnpparibas-am.com/en-hk>¹. The updated Hong Kong Offering Document will be available later.

What does this mean to you?

If you wish to continue to invest in the Investment Choice after considering the changes outlined above, you will not need to take any action. However, if you do not wish to maintain your investment in the Investment Choice, you may switch your existing holdings or redirect your future contribution allocations to alternative investment choice(s) by submitting an instruction to us, free of charge.

We recommend that you contact your licensed insurance intermediary in the first instance, who will be able to advise you of the alternative investment choice(s). For information on the fees and charges and the respective risk factors of our range of investment choices, please refer to the product brochure of the respective Schemes and the offering documents of the underlying funds made available by us upon request.

If you have any questions about this letter or your investment in the investment choice(s), please contact your licensed insurance intermediary, or you can call our customer care hotline at +852 3405 7150 or email us at helppoint.hk@hk.zurich.com and we will be happy to help.

Yours faithfully,

Zurich International Life Limited
(a company incorporated in the Isle of Man with limited liability)

Note: Please note investments involve risks. The value of any investment and the income from it can fall as a result of market and currency fluctuations and you could get back less than the amount originally invested.

¹ This website has not been reviewed by the Securities and Futures Commission of Hong Kong.

有關法巴基金（「法巴」）及該相關基金（定義見下文）之變更

此乃重要函件，務請您即時垂注。您如對本函件的内容有任何疑問，請尋求專業意見。

蘇黎世國際人壽保險有限公司
(於人島註冊成立之有限公司)

香港港島東華蘭路18號
港島東中心25-26樓

網址：www.zurich.com.hk

蘇黎世國際人壽保險有限公司是人島
Financial Services Authority所認可，
提供人壽保險、投資及保障產品。

於人島的註冊號碼為20126C。

註冊辦事處：Zurich House,
Isle of Man Business Park,
Douglas, Isle of Man, IM2 2QZ,
British Isles

我們就此函件所轉載資料的準確性承擔全部責任。

親愛的客戶：

我們謹此致函通知您有關法巴及該相關基金的變更。您已投資於該相關基金相應的投資選擇，其列於下表「受影響的投資選擇」中「投資選擇的名稱及代碼」一欄。

受影響的投資選擇

投資選擇（「該投資選擇」） 的名稱及代碼	相應的相關基金（「該相關基金」）名稱	適用計劃（統稱「計劃」）
蘇黎世國際法巴新興市場智取 債券基金（代碼：KAUSD）	法巴新興市場智取債券基金	<ul style="list-style-type: none">• 卓越精英國際投資計劃• 「樂安閑」計劃• 「樂安閑」III• 至尊國際儲蓄投資• 豐盛人生• 豐盛人生退休計劃

修訂事項

法巴的董事會（「該董事會」）已通知我們，以下對該相關基金的變動將會納入法巴下一版本的香港銷售文件（「該香港銷售文件」），除非下文另有註明，有關變動將於2025年8月12日生效。

法巴基金章程（「該基金章程」）第I冊的變動

該基金章程第I冊「附件3 – 投資風險」將加入與資本增值稅相關的風險因素，內容如下：

「投資者須注意，子基金進行的證券出售操作可能須繳納短期及長期資本增值稅。認購子基金股份的投資者應知悉，該等子基金的每股資產淨值可能因而受到該等稅項影響。這尤其適用於（但不限於）印度稅項（見第II冊）。」

該相關基金的風險範圍將特別加入該風險因素的參照說明。

該董事會確認，上述變動將不會導致管理該相關基金的費用水平或成本增加。此外，變動不會招致任何成本或開支。變動不會顯著改變該相關基金的特點及整體風險範圍。該相關基金的運作或管理方式並無改變，亦不會顯著損害現有投資者的權利或權益。

該香港銷售文件將作出更新以反映上述變動。現有的該香港銷售文件載於網站 <https://www.bnpparibas-am.com/zh-hk>¹。經更新的該香港銷售文件將於稍後提供。

¹ 此網站未經香港證券及期貨事務監察委員會審閱。

對您產生的影響

如您在考慮上述變更後仍希望繼續投資於該投資選擇，則無需就此修訂作出任何行動。倘若您不欲繼續投資於該投資選擇，可向本公司遞交轉換現有投資或重新指定未來供款分配至其他投資選擇的指示，費用全免。

我們建議您首先諮詢您的持牌保險中介人，以取得其他投資選擇的建議。有關本公司投資選擇（包括費用及收費，以及其相關風險因素）的詳情，請參閱相關計劃的產品介紹冊及相關基金的銷售文件，本公司會應要求提供上述銷售文件。

如您對本函件或投資選擇中的投資有任何疑問，請聯絡您的持牌保險中介人。您亦可致電+852 3405 7150或電郵至helppoint.hk@hk.zurich.com聯絡客戶服務部，我們將樂意為您效勞。

蘇黎世國際人壽保險有限公司
（於人島註冊成立之有限公司）
2025年7月31日

註：投資涉及風險，您的投資價值及收益可因市場及貨幣波動而下跌，有可能導致您不能取回所有投資款項。